NetworkNewsBreaks – Aileron Therapeutics Inc. (NASDAQ: ALRN) Closes Underwritten Registered Direct Offering
Aileron Therapeutics (NASDAQ: ALRN) is a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications. The company has announced the closing of its underwritten registered direct offering priced at-the-market under Nasdaq rules of 4,273,505 shares of its common stock and accompanying warrants to purchase an aggregate of 4,273,505 shares of common stock. Aileron secured aggregate gross proceeds of approximately $20 million, before deducting underwriting discounts and commissions and other offering expenses and excluding any proceeds that may be received from exercise of the warrants. Titan Partners Group, a…







